SUBSTITUTED PHENYL METHANONE DERIVATIVES

The present invention relates to compounds of the general formula

wherein

R ¹ is -OR ¹ , heterocycloalkyl, aryl or heteroaryl, which are unsubstituted or substituted by lower alkyl or halogen;

R is lower alkyl, lower alkyl substituted by halogen, or is -(CH ₂ ) _o -cycloalkyl;

R ² is -S(O) ₂ -lower alkyl, -S(O) ₂ NH-lower alkyl, NO ₂ or CN;

R ³ is aryl or heteroaryl, which are unsubstituted or substituted by one to three substituents, selected from the group consisting of lower alkyl, lower alkoxy, CN, NO ₂ , halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, aryl or sulfonamide;

X is a bond, -CH ₂ -, -NH-, -CH ₂ O- or -OCH ₂ -; n is 1 or 2; m is 1 or 2; o is O or 1;

and to pharmaceutically acceptable acid addition salts thereof.

The present invention relates to compounds of general formula I, to pharmaceutical compositions containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GIyT- 1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.

Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and

POP/05.02.2007

psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, , 28:325-33, 2000). For decades research has focused on the "dopaminergic hyperactivity" hypothesis which has led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., Exp. Opin. Ther. Targets, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al, Exp. Opin. Ther. Patents, 10(1): 75-98, 2000). This pharmacological approach poorly address negative and cognitive symptoms which are the redictors of functional outcome (Sharma T., BrJ. Psychiatry, 174(suppl. 28): 44-51, 1999). A complementary model of schizophrenia was proposed in the mid-1960s based upon the psychotomimetic action caused by the blockade of the glutamate system by compounds like phencyclidine (PCP) and related agents (ketamine) which are noncompetitive NMDA receptor antagonists. Interestingly, in healthy volunteers, PCP- induced psychotomimetic action incorporates positive and negative symptoms as well as cognitive dysfunction, thus closely resembling schizophrenia in patients (Javitt DC et al., Biol. Psychiatry, 45: 668-679, 1999). Furthermore transgenic mice expressing reduced levels of the NMDARl sub unit display behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., Cell, 98: 427-236, 1999J.

Glutamate neurotransmission, in particular NMDA receptor activity, plays a critical role in synaptic plasticity, learning and memory, such that NMDA receptors appear to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, Nature, 361: 31-39, 1993). Transgenic mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., Natur, 401- 63-69, 1999).

Thus, if a glutamate deficit is implicate in the pathophysiology of schizophrenia, enhancing glutamate transmission, in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.

The amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently present at a more constant level and seems to modulate/control the receptor for its response to glutamate.

One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses. Neurotransmitter transporters act by removing neurotransmitters from the extracellular space, and can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, Trends in Pharm. ScL, 23(8): 367-373, 2002). Glycine transporters, which form part of the sodium and chloride family of neurotransmitter transporters, play an important role in the termination of post-synaptic glycinergic actions and maintenance of low extracellular glycine concentration by reuptake of glycine into presynaptic nerve terminals and surrounding fine glial processes. Two distinct glycine transporter genes have been cloned (GIyT-I and GlyT-2) from mammalian brain, which give rise to two transporters with -50 % amino acid sequence homology. GIyT- 1 presents four isoforms arising from alternative splicing and alternative promoter usage (Ia, Ib, Ic and Id). Only two of these isoforms have been found in rodent brain (GIyT-Ia and GIyT-Ib). GlyT-2 also presents some degree of heterogeneity. Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains. GIyT-I is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS. GIyT- 1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function (Lopez - Corcuera B et al., MoI. Mem. Biol., 18: 13-20, 2001). Thus, one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GIyT- 1 transporter (Bergereon R. et al., Proc. Natl. Acad. ScL USA, 95: 15730-15734, 1998; Chen L. et al., /. NeurophysioL, 89(2): 691-703, 2003).

Glycine transporter inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders. The majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., Prog. Neurobiol, 67: 173-202, 2002), autistic disorders (Carlsson ML, /. Neural Trans,. 105: 525-535, 1998), cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001).

Thus, increasing activation of NMDA receptors via GIyT-I inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt- 1 inhibition, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

The preferred indications using the compounds of the present invention are schizophrenia, cognitive impairment and Alzheimer's disease.

Furthermore, the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers.

As used herein, the term "lower alkyl" denotes a saturated straight- or branched- chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon atoms.

As used herein, the term "cycloalkyl" denotes a saturated ring containing from 3 to

6 carbon atoms.

As used herein, the term "lower alkoxy" denotes a saturated straight- or branched- chain group containing from 1 to 6 carbon atoms as described above, which is connected via an oxygen atom.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

The term "aryl" denotes a monovalent cyclic aromatic hydrocarbon radical consisting of one or two fused rings in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl or biphenyl.

The term "heteroaryl" denotes a monovalent aromatic carbocyclic radical of one or two fused rings, which contains at least one heteroatom, for example pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl pyrazolyl, or 1,3,5-triazinyl.

The term "heterocycloalkyl" denotes a non aromatic hydrocarbon radical of one or two fused rings, which contains at least one heteroatom for example oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl.

The term "alkyl, substituted by halogen" denotes for example the following groups:

CF ₃ , CHF ₂ , CH ₂ F, CH ₂ CF ₃ , CH ₂ CHF ₂ , CH ₂ CH ₂ F, CH ₂ CH ₂ CF ₃ , CH ₂ CH ₂ CH ₂ CF ₃ , CH ₂ CH ₂ Cl, CH ₂ CF ₂ CF ₃ , CH ₂ CF ₂ CHF ₂ , CF ₂ CHFCF ₃ , C(CH ₃ ) ₂ CF ₃ , CH(CH ₃ )CF ₃ or CH(CH ₂ F)CH ₂ F.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.

Preferred compounds of the present application are compounds of formula I, wherein X is a bond and R is phenyl, which is unsubstituted or substituted by one to three substituents, selected from the group consisting of lower alkyl, lower alkoxy, CN, NO ₂ , halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, aryl or sulfonamide, for example the following compound rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l-methyl-ethoxy) -phenyl] -[3-(4- trifluoromethyl-phenyl) -pyrrolidin- 1 -yl] -methanone.

Preferred compounds of the present application are further those, wherein X is a - CH ₂ -and R is phenyl, which is unsubstituted or substituted by one to three substituents, selected from the group consisting of lower alkyl, lower alkoxy, CN, NO ₂ , halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, aryl or sulfonamide, for example the following compounds rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l-methyl-ethoxy) -phenyl] -[3-(4- trifluoromethyl-benzyl) -pyrrolidin- 1 -yl] -methanone, rac-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-phe nyl]-[3-(4- trifluoromethyl-benzyl) -pyrrolidin- 1 -yl] -methanone, rac-(4'-fluoro-4-methanesulfonyl-biphenyl-2-yl)-[3-(4-triflu oromethyl-benzyl)- pyrrolidin- 1 -yl] -methanone, rac-(2-cyclobutylmethoxy-5-methanesulfonyl-phenyl)-[3-(4-tri fluoromethyl-benzyl)- pyrrolidin-1-yl] -methanone or

rac-(2-cyclopentyloxy-5-niethanesulfonyl-phenyl)-[3-(4-tr ifluoroniethyl-benzyl)- pyrrolidin- 1 -yl] -methanone.

Preferred compounds of the present application are further those, wherein X is

-OCH ₂ -and R ³ is phenyl, which is unsubstituted or substituted by one to three substituents, selected from the group consisting of lower alkyl, lower alkoxy, CN,

NO ₂ , halogen, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, aryl or sulfonamide, for example the following compounds rac-[3-(4-chloro-phenoxymethyl)-pyrrolidin-l-yl]-[5-methanes ulfonyl-2-( (S) -2,2,2- trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone, rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -phenyl] -(3-p- tolyloxymethyl-pyrrolidin- 1 -yl) -methanone, rac-[3-(biphenyl-4-yloxymethyl)-pyrrolidin-l-yl]-[5-methanes ulfonyl-2-( (S) -2,2,2- trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone, rac-4-{ l-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -benzoyl] - pyrrolidin-3-ylmethoxy}-benzonitrile, rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -phenyl] -[3-(4-nitro- phenoxymethyl) -pyrrolidin- 1 -yl] -methanone, rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -phenyl] -[3-(4- trifluoromethoxy-phenoxymethyl) -pyrrolidin- 1 -yl] -methanone, rac-[3-(3,4-dichloro-phenoxymethyl) -pyrrolidin- 1-yl] - [5-methanesulfonyl-2-( (S) -2,2,2- trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone or rac-[5-methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -phenyl] -[3-(3- methoxy-phenoxymethyl) -pyrrolidin- 1 -yl] -methanone.

Another embodiment of the present invention are compounds, wherein X is -NH- or -CH ₂ O-.

The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes (a)-(c) described below, which process comprises a) reacting a compound of formula

with a compound of formula

in the presence of an activating agent such as TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate) to a compound of formula

wherein the substituents R , R and R are as defined above, and m and n are independently from each other 1 or 2;

b) reacting a compound of formula

with a compound of formula

R -OH under Mitsunobu conditions in the present of a phosphine to a compound of formula

wherein the substituents R ¹ , R ² and R ³ are as defined above, X is -OCH ₂ - and m and n are independently from each other 1 or 2;

c) reacting a compound of formula

with a compound of formula

R ³ -CH ₂ -Hal wherein Hal is an halogen atom like chlorine, bromine, iodine in the presence of a base such as sodium tert-butoxide to a compound of formula

wherein the substituents R ¹ , R ² and R ³ are as defined above, X is -CH ₂ O- and m and n are independently from each other 1 or 2;

and

if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.

The compounds of formula I may be prepared in accordance with process variants (a) - (c) and with the following schemes 1 - 3. The starting materials are either commercially available, are otherwise known in the chemical literature, or may be prepared in accordance with methods well known in the art.

Scheme 1

Compounds of general formula I can be prepared by reacting amine derivatives of formula II with an appropriately substituted acid of formula III in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate) and a base such as N-ethyldiisopropylamine (Scheme 1).

The amine compounds of formula II are either commercially available, are otherwise known in the chemical literature, or may be prepared using a variety of methods well known in the art.

The acids of formula III are either known in the chemical literature, or may be prepared using a variety of methods well known in the art.

Scheme 2

diphenyl- bu Di-tert-bu

I (X: OCH ₂ )

Compounds of general formula I can also be prepared by alternative routes as shown in Scheme 2. For instance, compounds of formula I (X: OCH2) can be prepared by reacting a hydroxy compound of formula IV with an alcohol of formula R ³ -OH, under Mitsunobu reaction conditions in the presence of a phosphine like triphenylphosphine or diphenyl-2-pyridylphosphine , and a dialkylazadicarboxylate like di-tert-butyl azodicarboxylate or diethylazadicarboxylate. The compounds of formula IV can be prepared by reacting amines of formula VI with an appropriately substituted acid of formula III in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-

1,1,3,3-tetramethyluroniumtetrafluoroborate) and a base such as N- ethyldiisopropylamine.

Scheme 3

R ³ sodium

I (X: CH ₂ O)

Compounds of general formula I can also be prepared by alternative routes as shown in Scheme 3. For instance, compounds of formula I (X: CH ₂ O) can be prepared by reacting a hydroxy compound of formula V with an alkylating agent of formula R -CH ₂ - Hal wherein Hal is an halogen atom like chlorine, bromine, iodine in the presence of a base like sodium tert-butoxide. The compounds of formula V can be prepared by reacting amines of formula VII with an appropriately substituted acid of formula III in the

presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-l, 1,3,3- tetramethyluroniumtetrafluoroborate) and a base such as N-ethyldiisopropylamine.

Isolation and purification of the compounds

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography, thick-layer chromatography, preparative low or high-pressure liquid chromatography or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the preparations and examples herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.

Salts of compounds of formula I

The compounds of formula I may be basic, for example in cases where the residue R ³ contains a basic group such as an aliphatic or aromatic amine moiety. In such cases the compounds of formula I may be converted to a corresponding acid addition salt.

The conversion is accomplished by treatment with at least a stoichiometric amount of an appropriate acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids suchas acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. Typically, the free base is dissolved in an inert organic solvent such as diethyl ether, ethyl acetate, chloroform, ethanol or methanol and the like, and the acid added in a similar solvent. The temperature is maintained between 0 ⁰ C and 50 ⁰ C. The resulting salt precipitates spontaneously or may be brought out of solution with a less polar solvent.

The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.

The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GIyT-I).

The compounds were investigated in accordance with the test given hereinafter.

Solutions and materials

DMEM complete medium: Nutrient mixture F- 12 (Gibco Life-technologies), fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Hygromycin 0.6 mg/ml (Gibco life technologies), Glutamine 1 mM Gibco life technologies)

Uptake buffer (UB): 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl ₂ , 2.5 mM KCl, 2.5 mM MgSO ₄ , 10 mM (+) D-glucose. Flp-in™-CHO (Invitrogen Cat n° R758-07)cells stably transfected with mGlyTlb cDNA.

Glycine uptake inhibition assay (mGlvT-lb)

On day 1 mammalian cells, (Flp-in™-CHO), transfected with mGlyT-lb cDNA , were plated at the density of 40,000 cells/well in complete F- 12 medium, without hygromycin in 96-well culture plates. On day 2, the medium was aspirated and the cells were washed twice with uptake buffer (UB). The cells were then incubated for 20 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine , (iii) a concentration of a potential inhibitor. A range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g. IC50, the concentration of the competitor inhibiting glycine uptake of 50 %). A solution was then immediately added containing [ H] -glycine 60 nM (11-16 Ci/mmol) and 25 μM non-radioactive glycine. The plates were incubated with gentle shaking and the reaction was stopped by aspiration of the mixture and washing (three times) with ice-cold UB. The cells were lysed with scintillation liquid, shaken 3 hours and the radioactivity in the cells was counted using a scintillation counter.

The preferred compounds show an IC50 (μM) at GIyT-I in the range of 0.09 - 0.50, as shown in the table below.

The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose,corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if

desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease.

The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.

Tablet Formulation (Wet Granulation)

Item Ingredients mg/ tablet

5 mg 25 mg 100 mg 500

1. Compound of formula I 5 25 100 500

2. Lactose Anhydrous DTG 125 105 30 150

3. Sta-Rx 1500 6 6 6 30

4. Microcrystalline Cellulose 30 30 30 150

5. Magnesium Stearate 1 1 1 1

Total 167 167 167 831

Manufacturing Procedure

1. Mix items 1, 2, 3 and 4 and granulate with purified water.

2. Dry the granules at 50 ⁰ C.

3. Pass the granules through suitable milling equipment.

4. Add item 5 and mix for three minutes; compress on a suitable press.

Capsule Formulation

Item Ingredients mg/capsule

5 mg 25 mg 100 mg 500

1. Compound of formula I 5 25 100 500

2. Hydrous Lactose 159 123 148 ---

3. Corn Starch 25 35 40 70

4. Talc 10 15 10 25

5. Magnesium Stearate 1 2 2 5

Total 200 200 300 600

Manufacturing Procedure

1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.

2. Add items 4 and 5 and mix for 3 minutes.

3. Fill into a suitable capsule.

The following examples illustrate the invention but are not intended to limit its scope. The following abbreviations were used in the examples: TBTU: 2- ( 1 H-benzotriazole- 1 -yl) -1,1 ,3,3-tetramethyluroniumtetrafluoroborate;

Synthesis of intermediates of formula II

Example Al Rac- 3- (4-Trifluoromethyl-phenyl) -pyrrolidine

a) rac-3-Hvdroxy-3-(4-trifluoromethyl-phenyl)-pyrrolidine-l-car boxylic acid ethyl ester

364 mg magnesium was suspended in 2ml ether, under nitrogen. 150 ul 4-bromobenzo- trifluoride was added and then a solution of 12.6 mmol 4-bromobenzotrifluoride in 1.5 ml ether was added dropwise over a period of 10 minutes at room temperature. The mixture came mildly exothermic and turned red-brown while the grignard reagent formed during 1.5h of stirring. The mixture was cooled down to 0 ⁰ C. A solution of 12.5 mmol l-N-ethoxycarbonyl-3-pyrrolidone in 14ml ether was added dropwise. The reaction mixture was allowed to come to room temperature and stirred for 2h30. 20% NH ₄ Cl was added dropwise, at 0 ⁰ C, to quench the reaction. The mixture was allowed to warm to room temperature. The aqueous layer was extracted 3 times with ether. The combined organic phases were washed with water and brine, dried over Na2SO ₄ and evaporated. The residue was purified on silica gel (eluent: heptane-ethyl acetate 1/1) to yield the title compound (61%) as a yellow solid. MS (m/e): 362.2 ([M+59], 100%). b) rac-3-(4-Trifluoromethyl-phenyl)-pyrrolidin-3-ol

To a solution of 1.98 mmol rac-3-Hydroxy-3-(4-trifluoromethyl-phenyl)-pyrrolidine-l- carboxylic acid ethyl ester in 15ml dioxane., was added 8ml of a 2.5N solution of KOH in butanol. The solution was stirred under reflux for 2 hours. The solvent was removed in vacuo and the residue was taken in water. The aqueous phase was extracted 3 times with dichloromethane. The combined organic phases were dried over Na2SO ₄ , evaporated and

dried. The compound was suspended in hexane/ ether (~2:1), filtered and rinsed with hexane to yield the title compound (57%) as a light brown solid MS (m/e): 232.1 ( [M+l], 100%).

c) 3-(4-Trifluoromethγl-phenγl)-2,5-dihγdro-lH-pγrrole

To a suspension of 0.43 mmol rac-3-(4-Trifluoromethyl-phenyl)-pyrrolidin-3-ol in 0.4 ml dichloromethane under argon, was added 0.4 ml TFA. The reaction mixture was stirred at reflux for 5 days and concentrated. The residue was dissolved in ethyl acetate and NaOH 2N was added until pH 9-10. The organic phases were dried over Na ₂ SU ₄ and evaporated to yield the title compound ( 18%) as an oil MS (m/e): 214.2 ( [M+l], 100%).

d) 3-(4-Trifluoromethγl-phenγl) -pyrrolidine

0.08 mmol 3-(4-Trifluoromethyl-phenyl)-2,5-dihydro-lH-pyrrole was dissolved in MeOH and HCl in ether was added until pH 1. After 5 minutes stirring, the solvents were evaporated. To a solution of this salt in 0.7 ml methanol under argon was added 2mg Pd/C 10% and the mixture was hydrogenated under atmospheric pressure of hydrogen at room temperature for 4 h. The mixture was cooled, flushed with argon, diluted with methanol, filtered and the solvent was removed in vacuo to yield the title compound (64%) as an oil MS (m/e): 216.3 ( [M+l], 100%).

Example A2

Rac-3-o-Tolyl-pyrrolidine

a) rac-S-Hydroxy-S-o-tolyl-pyrrolidine-l-carboxylic acid tert-butyl ester

Prepared in analogy to Example Al (a) from N-boc-3-pyrrolidinone and o-tolyl- magnesiumbromide to yield the title compound as an light yellow oil. MS (m/e): 278.2 (M+H ⁺ , 100%).

b) 3-o-Tolyl-2,5-dihydro-lH-pyrrole

Prepared in analogy to Example Al(c) from rac-3ηydroxy-3-o-tolyl-pyrrolidine-l- carboxylic acid tert-butyl ester to yield the title compound as an orange oil. MS (m/e): 160.2 (M+H ⁺ , 100%).

c) Rac-3-o-Tolyl-pyrrolidine

Prepared in analogy to Example B3 from 3-o-Tolyl-2,5-dihydro-lH-pyrrole to yield the title compound as a yellow oil. MS (m/e): 162.3 (M+H ⁺ , 100%).

Example A3 Rac-3-(4-Trifluoromethyl-benzyl)-pyrrolidine acetic acid

Prepared in analogy to Example Al(d) from l-Benzyl-3-(4-trifluoromethyl-benzyl)- pyrrolidine (CAS: 336182-64-0) by replacing HCl with acetic acid to yield the title compound as an light brown oil. MS (m/e): 230.4 (M+H ⁺ , 100%).

Example A4

Rac-3-(3-Fluoro-benzyl)-pyrrolidine

Prepared in analogy to Example Al(d) from l-Benzyl-3-(3-fluoro-benzyl)-pyrrolidine to yield the title compound as a colorless oil. MS (m/e): 180 (M+H ⁺ , 100%).

Example A5 Rac-pyrrolidin-3-yl-(4-trifluoromethyl-phenyl)-amine hydrochloride

Prepared in analogy to Example Al(d) from (l-Benzyl-pyrrolidin-3-yl)-(4- trifluoromethyl-phenyl) -amine (CAS: 816468-46-9) to yield the title compound as a white solid. MS (m/e): 230.9 (M+H ⁺ , 100%).

Example Bl

4'-Fluoro-4-methanesulfonyl-biphenyl-2-carboxylic acid

A mixture of 6.1 mmol 2-Iodo-5-methanesulfonyl-benzoic acid (CAS: 845616-08-2), 12.2 mmol 4-fluorobenzeneboronic acid, 18.4 mmol sodium carbonate and 0.3 mmol palladium (II) acetate in 30 ml water was stirred at room temperature for 48 hours. The mixture was filtered and the filtrate was acidified with HCl 37%. The mixture was stirred at room temperature for 30 minutes. The solid was filtered, washed with water and dried to provide the title compound (92%). Yellow solid. MS (m/e): 293.2 ( [M-H], 100%).

Example B2 5-Methanesulfonyl-2-(4-methyl-pyrazol-l-yl) -benzoic acid

a) 5-Methanesulfonγl-2-(4-methγl-pγrazol-l-γl)-benzoic acid methyl ester

In a glass tube was added successively 0.29 mmol 2-Iodo-5-methanesulfonyl-benzoic acid methyl ester (CAS: 847547-09-5), 0.35 mmol 4-methylpyrazole, 0.59 mmol potassium carbonate, 0.06 mmol CuI and a solution of 0.12 mmol trans- 1,2-diaminocyclohexane in 0.4 ml dioxane (degased). The tube was filled with argon and sealed with a cap. The reaction mixture was heated at 120 ⁰ C overnight. The reaction mixture was cooled down to room temperature, dichloromethane and water were added. The aqueous phase was extracted 2 times with dichloromethane. The combined organic phases were dried over sodium sulfate and evaporated. The crude compound was purified on a 1Og Flashpack cartridge. Eluent: Heptane/ethylacetate to provide the title compound (57%) as a light yellow oil. MS (m/e): 295.0( [M+H] ⁺ , 100%).

(b) 5-Methanesulfonyl-2-(4-methyl-pyrazol-l-yl)-benzoic acid

To 2.08 mmol 5-Methanesulfonyl-2-(4-methyl-pyrazol-l-yl)-benzoic acid methyl ester in 2.2 ml THF and 2.2 ml water was added 3.12 mmol lithium hydroxide and the reaction mixture was stirred at RT for 2 hours. After such time the solvent was removed in vacuo, the residue was taken in water and acidified by addition of 3N HCl to yield after filtration the title compound as a white solid (88%). MS (m/e): 279.1 ( [M-H], 100%).

Example B3 5-Methanesulfonyl-2-(tetrahydro-pyran-4-yl) -benzoic acid

To 0.07 mmol 2-(3,6-Dihydro-2H-pyran-4-yl)-5-methanesulfonyl-benzoic acid (CAS: 847547-05-1) in 0.5 ml methanol under argon was added 20 mg Pd/C, followed by 0.07 mmol ammonium formate. The reaction mixture was refluxed for 30 minutes, filtered and evaporated. Water was added and the solution was acidified with 2N HCl to pH 1. The aqueous phase was extracted with dichloromethane. The combined organic phases were dried over Na2SU4 and evaporated to yield the title compound as a colorless oil. MS (m/e): 283.2( [M-H], 100%).

Example Cl Rac-(3-Hydroxymethyl-pyrrolidin-l-yl)-[5-niethanesulfonyl-2- ((S)-2,2,2-trifluoro-l- methyl-ethoxy)-phenyl] -methanone

To a solution of 0.01 mol 5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l-methyl-ethoxy)- benzoic acid (CAS: 845616-82-2) in 40 ml N,N-dimethylformamide were added successively 3.57 g TBTU, 8.5 ml N-ethyldiisopropylamine and 1 g rac-pyrrolidin-3-yl- methanol (CAS: 5082-74-6). The reaction mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The mixture was taken in ethyl acetate and washed twice with water and twice with saturated NaHCU3. The organic phase was dried over Na2SC"4 and filtered. The solvent was evaporated. The crude oil was purified on silica gel (eluent: ethyl acetate) to yield the title compound as an off white foam. MS (m/e): 396.1 (M+H ⁺ , 100%).

Synthesis of compounds of formula I

In analogy to Example Cl, compounds 1 to 27 of the following table were prepared from the acid derivatives and amine derivatives:

Example 28

rac-[5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l-methyl-et hoxy)-phenyl]-[3-(4- trifluoromethyl-phenoxymethyl)-pyrrolidin-l-yl]-methanone

To a solution of 70 mg rac-(3-Hydroxymethyl-pyrrolidin-l-yl)-[5-methanesulfonyl-2- ( (S) -2,2,2-trifluoro-l-methyl-ethoxy) -phenyl] -methanone (Example Cl) in 1.4 ml tetrahydrofuran were added 30 mg 4-hydroxybenzotrifluoride and 50 mg diphenyl-2- pyridylphosphine. 43 mg Di-tert-butyl azodicarboxylate was added. The mixture was stirred at 70 ⁰ C for 23 hours. The solvent was removed in vacuo. The oil was purified on silica gel (eluent: ethyl acetate) to yield a yellow gum. The gum was dissolved in ethyl acetate. The solution was washed 3 times with HCl 5N, once with water, dried over Na2SU4, filtered and concentrated in vacuo to provide the title compound as a light yellow foam. MS (m/e): 540.3 (M+H ⁺ , 100%).

In analogy to Example 28, compounds 29 to 39 of the following table were prepared from rac-(3-Hydroxymethyl-pyrrolidin-l-yl)-[5-methanesulfonyl-2-( (S)-2,2,2-trifluoro-l- methyl-ethoxy) -phenyl] -methanone (Example Cl) and the phenol reagent:

Example 40 rac-[5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l-methyl-ethox y)-phenyl]-[3-(4- trifluoromethyl-benzyloxy) -pyrrolidin- 1-yl] -methanone a) rac-(3-Hvdroxy-pyrrolidin-l-yl)-[5-niethanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl - ethoxy) -phenyll -methanone

Prepared in analogy to Example Cl from 5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l- methyl-ethoxy) -benzoic acid (CAS: 845616-82-2) and rac-3-pyrrolidinol. The crude material was crystallized with dichoromethane to provide the title compound as white solid. MS (m/e): 382.3 (M+H ⁺ , 100%).

b) rac-[5-Methanesulfonyl-2-( (S) -2,2,2-trifluoro-l -methyl-ethoxy) -phenyll -[3-(4- trifluoromethyl-benzyloxy) -pyrrolidin- 1 -yll -methanone

To a solution of 100 mg rac-(3-Hydroxy-pyrrolidin-l-yl)-[5-methanesulfonyl-2-((S)- 2,2,2-trifluoro-l-methyl-ethoxy) -phenyl] -methanone in ImI DMF under argon at 0°C, was added 0.042 ml 4-(trifluoromethyl)benzyl chloride, followed by 31.2 mg sodium - tert-butoxide. The reaction mixture was stirred at room temperature for 2 days and evaporated. The residue was dissolved in ethyl acetate and was extracted 2 times with water. The organic phase was dried over Na2SO4 and evaporated. The residue was purified on silica gel (eluent: ethyl acetate) to yield the title compound as an oil. MS (m/e): 540.2 (M+H ⁺ , 100%).